
Opinion|Videos|May 5, 2025
Lp(a) Testing: Prevalence and Strategies to Improve Uptake
Author(s)Nihar Desai, MD, MPH
Nathan Wong, PhD
Nathan Wong, PhD
Experts discuss the current prevalence of lipoprotein(a) (Lp[a]) testing in the US, both in the general population and among those with established atherosclerotic cardiovascular disease (ASCVD), its commonality within health plans, and how payers, population health decision makers, and provider groups can integrate Lp(a) testing into broader population health management strategies.
Advertisement
Video content above is prompted by the following:
- Currently, how prevalent is Lp(a) testing in the US, both in the overall population and among those with established ASCVD?
- How common is Lp(a) testing within the health plans that you work with?
- How can payers, population health decision makers working at health systems, and provider groups infuse Lp(a) testing into their larger population health management infrastructure?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Leucovorin Treatment Expansion for Autism Symptoms Under FDA Review
2
FDA Approves Imlunestrant for ER+ and HER2-Negative Breast Cancer
3
Supporting Pharmacy Residents in Completing Research Projects at UC Davis: Jeremiah J. Duby, PharmD, BCPS, BCCCP
4
Marathon Health, Medbridge Partner to Launch Integrated Virtual MSK Care Program
5